Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice

Novel partners for established immune checkpoint inhibitors in the treatment of cancer are needed to address the problems of primary and acquired resistance. The efficacy of combination RANKL and CTLA4 blockade in antitumor immunity has been suggested by recent case reports in melanoma. Here, we pro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2017-10, Vol.23 (19), p.5789-5801
Hauptverfasser:	Ahern, Elizabeth, Harjunpää, Heidi, Barkauskas, Deborah, Allen, Stacey, Takeda, Kazuyoshi, Yagita, Hideo, Wyld, David, Dougall, William C, Teng, Michele W L, Smyth, Mark J
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Antibodies Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antigens, CD - genetics Antigens, CD - immunology Cancer Case reports CD8 antigen CD8-Positive T-Lymphocytes - immunology Clinical trials Combinatorial analysis CTLA-4 Antigen - genetics CTLA-4 Antigen - immunology CTLA-4 protein Cytokines - genetics Dendritic cells Dendritic Cells - immunology Disease control Effectiveness Experimental design Fc receptors Gene Expression Regulation, Neoplastic - immunology Humans Immune checkpoint inhibitors Immunity Immunoglobulin G Immunotherapy Infiltration Lymphocytes Lymphocytes - immunology Lymphocytes T Lymphocytes, Tumor-Infiltrating - immunology Macrophages Medical research Melanoma Melanoma, Experimental - genetics Melanoma, Experimental - immunology Melanoma, Experimental - therapy Metastases Mice Natural killer cells RANK Ligand - genetics RANK Ligand - immunology Receptor Activator of Nuclear Factor-kappa B - genetics Receptor Activator of Nuclear Factor-kappa B - immunology Receptors Solid tumors Suppressor cells T-Lymphocytes, Regulatory - immunology TRANCE protein Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!